News & Media

Read more about the article Pharma’s Blind Spot: Successfully Using AI To Drive Drug Development
News

Pharma’s Blind Spot: Successfully Using AI To Drive Drug Development

Jon Hu Forbes Councils Member Artificial intelligence (AI) has penetrated nearly every industry, but the pharmaceutical industry could arguably benefit from AI the most. According to the results of a study performed by Insider Intelligence, AI has the potential to curb drug discovery costs for pharma companies by nearly 70%. It can do this by making accurate, more nuanced predictions about a disease or drug. However, if the data feeding into…

Comments Off on Pharma’s Blind Spot: Successfully Using AI To Drive Drug Development
June 15, 2022
Podcast

Podcast: Developing Therapies with Transomics

Ayesha Rashid and the editorial team at the Xtalks Life Science podcast spoke with Dr. Samantha Dale Strasser, chief scientific officer and co-founder of biotech start-up Pepper Bio. The company is working to develop therapeutics in the areas of oncology, neurodegenerative disease and inflammatory conditions using a ‘transomics’ drug discovery approach. This involves the integrated analysis of several layers of biological data, including genomic, proteomic, transcriptomic and phosphoproteomic data using…

Comments Off on Podcast: Developing Therapies with Transomics
June 1, 2022
Podcast

Podcast: Using Transomics to Treat the Untreatable

William Schoeffler, host of the Human Interest podcast, sits down with co-founder and CEO of Pepper Bio, to discuss the company’s computational drug discovery platform and how its transomics approach can lead to the discovery and development of safer and more effective drugs. Listen here to learn how Pepper is changing drug discovery. Source: Human Interest Podcast // See original post here.

Comments Off on Podcast: Using Transomics to Treat the Untreatable
April 8, 2022
Podcast

Podcast: Changing Drug Discovery with Transomics

Neil Littman from the Bioverge Podcast sits down with Samantha Dale Strasser, co-founder and chief scientific officer of Pepper Bio, to discuss the company’s computational drug discovery platform and how its transomics approach can lead to the discovery and development of safer and more effective drugs. Listen here to learn how Pepper is changing drug discovery. Source: Bioverge Podcast // See original post here.

Comments Off on Podcast: Changing Drug Discovery with Transomics
March 31, 2022
Read more about the article The Root Cause Of Pharma’s Drug Development Problem
News

The Root Cause Of Pharma’s Drug Development Problem

Jon Hu Forbes Councils Member Everyone likes to point fingers at big pharma. They’ll point to how much money it takes to develop a single drug (up to $2.8 billion on average)—or point to how a drug caused severe, long-term side effects that result in it coming off the market—ultimately throwing that money down the drain. But ironically, they’re missing the point. The problem isn’t the cost; the cost is an effect…

Comments Off on The Root Cause Of Pharma’s Drug Development Problem
March 15, 2022
Read more about the article Stanford Lab Aligns With Pepper Bio To Target Tough Cancers
News

Stanford Lab Aligns With Pepper Bio To Target Tough Cancers

The drug discovery firm will work with the Dean Felsher laboratory, using the company's transomics platform to discover therapies for untreatable cancers. Researchers at Stanford University's Dean Felsher laboratory have announced plans to collaborate with drug discovery company Pepper Bio in an effort to identify therapeutic targets for untreatable lymphatic and liver cancers. With the help of Pepper Bio's platform on phosphoproteomics, the collaborators reportedly aim to identify and validate…

Comments Off on Stanford Lab Aligns With Pepper Bio To Target Tough Cancers
March 3, 2022